Skip to main content

Table 1 Characteristics of experienced patients not receiving MVC at the time of tropism test performance

From: Clinical impact of tropism testing in a real-life cohort of HIV infected patients: a retrospective observational study

  Total (n = 366) MVC prescription (n = 110) No MVC prescription (n = 256) p
Test performance before 2011 164 (44.8) 75 (68.2) 89 (34.8) < 0.01
Age (years) 47 (10.9) 49 (10) 47 (11.3) 0.05
Male sex 263 (71.9) 80 (72.7) 183 (71.5) 0.81
Risk group     0.13
 Heterosexual 175 (47.8) 50 (45.5) 125 (48.8)  
 Homosexual 145 (39.6) 50 (45.5) 95 (37.1)  
 Other 46 (12.6) 10 (9.1) 36 (14.1)  
CDC stage     0.03
 A 185 (50.6) 46 (41.8) 139 (54.3)  
 B 84 (22.9) 34 (30.9) 50 (19.5)  
 C 97 (26.5) 30 (27.3) 67 (26.2)  
CD4 count (/mm3) 515.9 (286.5) 539.7 (262.5) 505.8 (295.9) 0.27
Undetectable viral load 155 (42.3) 52 (33.5) 103 (66.5) 0.21
Time between ART initiation and tropism (years) 9.9 (6.1) 10.9 (6) 9.4 (6.1) 0.03
Time between last ART change and tropism (years) 2.2 (2.2) 2.4 (2) 2.1 (2.3) 0.09
Number of previous ART regimens 6 (5.3) 7.9 (7.1) 5.2 (4) < 0.01
Number of ART families with resistance 1.1 (1) 1.2 (1.1) 1.1 (0.9) 0.23
Reason for tropism performance     < 0.01
 Virological failure 170 (46.4) 38 (34.5) 132 (51.6)  
 Side effect or interaction 128 (35) 50 (45.5) 78 (30.5)  
 Neurological diffusion 14 (3.8) 7 (6.4) 7 (2.7)  
 Sparing strategy or simplification 41 (11.2) 10 (9.1) 31 (12.1)  
 Immunological failure 13 (3.6) 5 (4.6) 8 (3.1)  
  1. Mean (standard deviation) and number (%)
  2. MVC Maraviroc, ART Anti Retroviral Therapy